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A multisystem inflammatory syndrome (MIS) occurring several weeks after SARS-CoV-2 infection 
and that can include severe acute heart failure was recently reported in children (MIS-C).1, 2 In adults 
with acute severe heart failure, we have identified a similar syndrome and describe presenting 
characteristics, diagnostic features and early outcomes. Our data also complement recently presented 
reports of MIS syndromes in adults (MIS-A).3  
 
The recognition that three patients presenting with fulminant myocarditis also had clinical features of 
COVID19 but were negative for SARS-CoV-2 RT-PCR, was made during recruitment for a study of 
cardiac injury associated with SARS-CoV-2. To identify implications for patient care, we audited 
digital records to identify similar presentations to Barts Health NHS Trust and Guy’s and St Thomas’ 
NHS Trust between March and September 2020. Formal ethics approval was not required. All cases 
had stored serum for antibody testing, and included 9 ‘Subjects’ (cases 1-9) with (i) acute cardiac 
decompensation, (ii) negative RT-PCR for SARS-CoV-2, (iii) markedly elevated serum troponin, and 
(iv) significantly raised inflammatory markers.  We also studied 3 ‘Controls’ (cases 10-12) with acute 
heart failure and SARS-CoV-2 antibodies, but without all the other features.  
 
Subjects were more often male (7/9), of Black African ancestry (7/9), and mean age was 36 years (23-
53). Both female Subjects (cases 9,11) presented during or shortly after pregnancy, one of whom had 
gestational diabetes. One male case included significant co-morbidity (case 4, hypertension secondary 
to primary hyperaldosteronism).  
 
Presenting features in Subjects included febrile illness (all, 1–7 days), dyspnoea (5/9), gastrointestinal 
involvement (pain, diarrhoea or vomiting in 8/9, with imaging evidence of enteritis in 3/8), pulmonary 
infiltrates (8/9), and muco-cutaneous involvement (4/9). A recent history of typical COVID19 
symptoms followed by recovery was present in 4/9, and included RT-PCR proven infection in one. 
Subjects had multiple negative SARS-CoV-2 RT-PCRs during their cardiac admission (4·6 tests, range 
3-8). SARS-CoV-2 antibody testing on stored serum taken 4.2 days (0-20) after admission was positive 
in 7/9.  Elevated C-reactive protein (CRP, 38-89 times upper limit of normal [ULN]), ferritin (0·2-16 
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ULN), neutrophils (1·5-6·6 ULN), and neutrophil:lymphocyte ratio (4·5-42) were striking (Figure 1, 
appendix).  
 
Subjects deteriorated rapidly after admission, including eight transferring into tertiary cardiac intensive 
care (ICU) 2.9 days after admission (1-6 days); one Subject (case 5) was transferred to the local ICU 
one day after admission. Therapies included pharmacological (8/9) and mechanical (2/9) circulatory 
support. Corticosteroids (6/9) with or without intravenous immunoglobulin (IVIG, 2/6) were given 
frequently, as were broad spectrum antimicrobials (7/9). One Subject received anakinra. 
 
Severe left ventricular (LV) systolic impairment (Figure 1) was present on admission echocardiography 
with ejection fraction (LVEF) 24% (10-35%). Peak troponin ranged between 6-208 ULN, and alongside 
inflammatory markers and clinical status demonstrated rapid improvement following ICU admission 
and therapy (Figure 1). The average length of ICU stay was nine days (2-25 days). 
 
Acute cardiac MRI (CMR1), available for all Subjects 11 days (3-24) following ICU admission, 
demonstrated LVEF 57% (42-70%). Late gadolinium enhancement (LGE, 6/9), elevated T1 (7/7), and 
elevated T2 (6/9) were present in most Subjects (Figure 1). Convalescent CMR (CMR2) in six Subjects 
103 days (48-155) following CMR1 detected normal LVEF (57-70%) in all except case 4, where 
systolic function again deteriorated. Comparing paired data, LVEF recovered markedly between 
admission and CMR1 (22% vs. 53%; p=0·00004), but was similar between CMR1 and CMR2 (53% 
vs. 58%; p=0·42). Abnormal LGE (4/6 to 1/6), T1 (6/6 to 4/6) and T2 (4/5 to 1/5) were less frequent on 
CMR2 (paired data: T1 1210 to 1044msec, p=0·004; T2 58 to 50msec, p=0·007); T1 and T2 remained 
elevated in case 4.  
 
We propose that this series describes cardiogenic shock due to a post-COVID19 multisystem 
inflammatory syndrome in adults (MIS-A). Similarities with MIS-C include frequent GI involvement, 
pulmonary infiltrates, muco-cutaneous involvement, and significantly elevated inflammatory 
markers.1,2 Detectable antibody and RNA absence is consistent with recent recovery following infection 
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in London naive to SARS-CoV-2 before March 2020. Not all Subjects had detectable SARS-CoV-2 
antibody, another feature common to MIS-C, and one with important clinical implications. A 
preponderance of male and (UK) minority ethnic group patients mark another similarity with MIS-C. 
As in similar MIS-C cases, a rapid and profound improvement in cardiac function closely followed 
initiation of supportive, antimicrobial, and/or immunomodulatory therapy.  
 
The three Controls (cases 10-12) help define the key features of cardiogenic shock in MIS-A, and 
illustrate diagnostic challenges arising from the heterogeneous aetiology of acutely presenting heart 
failure. Presenting within weeks of SARS-CoV-2 infection, none demonstrated extreme elevations of 
inflammatory markers, GI symptoms or muco-cutaneous features. Only Control case 12 had very 
elevated cardiac troponin, and had lymphocytic myocarditis with parvovirus on biopsy. With increasing 
population seropositivity, the Controls also emphasise that anti-SARS-CoV-2 IgG will make a limited 
contribution to MIS-A diagnosis.  
 
Our study’s limitations include selection bias; notably, lethal and milder cases are not represented. All 
therapeutic interventions are uncontrolled and causality is not inferred. Two Subjects were negative for 
SARS-CoV-2 antibody, consistent with seropositivity prevalence in MIS-C. (1,2) This may reflect test 
sensitivity, failed/delayed seroconversion, and/or early declines in antibody levels. Alternatively, 
initiating events other than SARS-CoV-2 may be responsible.  
 
However, this communication’s primary purpose is to highlight a novel clinical presentation of a multi-
system disorder that can have life-threatening features, yet may respond adroitly to therapy. Potential 
factors responsible for the delay in identifying this syndrome in adults and/or diagnosing individual 
cases include: 1) severe cardiac involvement is likely to be rare, 2) negative RT-PCR testing at the time 
of the cardiac presentation, 3) limited diagnostic role for antibody testing: unavailable early in the 
pandemic, poor specificity subsequently, 4) attribution of systolic impairment to pre-existing cardiac 
disease, 5)  high frequency of COVID19-related acute myocardial injury and multiplicity of its causes: 
up to 40% of hospitalised patients have elevated troponin4 and 6) difficulties obtaining 
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complex/invasive diagnostic investigations in ICU patients during the pandemic. Finally, as MIS-C is 
a wide-spectrum disorder, including variable severity and involving multiple systems,2 adult 
practitioners should also be alert to the likelihood that MIS-A will be heterogenous and may not include 
cardiac involvement.  
 
This study was not externally funded. An associated study (ROAD-COVID19, NCT04340921) is supported by 




Figure 1. Temporal changes in selected markers of systemic inflammation and myocardial damage in 
Subjects (cases 1-9, solid lines) and Controls (cases 10-12, dotted lines).  
A-C: Biochemical markers. Day 0 represents the time-point when corticosteroids were administered, 
or ICU admission for the cases that did not receive steroids. Data from a prior acute COVID19 
admission are available for two cases. (A) Serum Troponin T; (B) Serum ferritin; (C) C-reactive protein. 
D-E: Imaging features in Subject cases. Echocardiography was obtained at ICU admission, CMR1 11 
days (range 3-24) after ICU admission and CMR2 103 days (48-155) following CMR1. D: For 
echocardiography, the median value is used whenever EF was reported within a range. E: The highest 
T1 (left-sided y-axis) and T2 (right-sided y-axis) values reported for each Subject are plotted.    




Table 1: Case summaries including Subjects (cases 1-9) and Controls (cases 10-12).  
BSA – broad spectrum antibiotics, CMR – cardiac magnetic resonance imaging, CT – computed 
tomography, CTCA – CT coronary angiogram, CXR – chest x-ray, ECMO – extracorporeal membrane 
oxygenation as veno-veno (VV) or veno-arterial (VA), EMB – endomyocardial biopsy, ICU - intensive 
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care unit, LGE – late gadolinium enhancement, LV – left ventricle, PE – pulmonary emboli, PMH – 
past medical history, TTE – transthoracic echocardiography. 
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-
C
ar
ib
be
an
; 
no
 P
M
H
N
o 
pr
od
ro
m
al
 s
ym
pt
om
s
4 
da
ys
 m
ya
lg
ia
, 
fe
ve
rs
, 
he
ad
ac
he
s 
an
d 
di
ar
ho
ea
R
es
pi
ra
to
ry
 f
ai
lu
re
 
an
d 
ca
rd
io
ge
ni
c 
sh
oc
k
V
en
ti
la
ti
on
 (
4 
da
ys
)
M
il
ri
no
ne
, 
no
ra
dr
en
al
in
e,
 
le
vo
si
m
en
da
n;
 B
S
A
; 
IV
IG
, 
an
ak
in
ra
, 
m
et
hy
lp
re
dn
is
ol
on
e
T
T
E
: 
B
i-
ve
nt
ri
cu
la
r 
im
pa
ir
m
en
t 
(L
V
E
F
 2
5%
).
 
C
X
R
: 
bi
la
te
ra
l 
lu
ng
 
ch
an
ge
s.
 C
T
C
A
 n
or
m
al
S
ca
n 
1(
IC
U
 +
 8
 d
ay
s,
 T
nT
 3
4n
g/
l)
: 
L
V
E
F
57
%
, 
no
rm
al
 
T
1 
an
d 
T
2,
 e
pi
ca
rd
ia
l 
L
G
E
. 
C
R
P
 3
79
 m
g/
L
; 
T
nT
 4
31
 n
g/
L
; 
F
er
ri
ti
n 
13
56
 
m
cg
/L
; 
ne
ut
ro
ph
il
s 
20
x1
09
/l
R
T
-P
C
R
: 
4 
x 
ne
ga
ti
ve
; 
an
ti
bo
dy
 p
os
it
iv
e
6 
da
ys
; 
fu
ll
 
re
co
ve
ry
C
as
e 
8:
 3
3;
 f
em
al
e;
 S
ou
th
-
A
si
an
; 
ge
st
at
io
na
l 
di
ab
et
es
, 
 C
-
se
ct
io
n 
at
 3
6 
w
ee
ks
 g
es
ta
ti
on
.
N
o 
pr
od
ro
m
al
 s
ym
pt
om
s
C
he
st
 p
ai
n,
 d
ys
pn
oe
a,
 
de
sa
tu
ra
ti
on
 2
4 
ho
ur
s 
fo
ll
ow
in
g 
el
ec
ti
ve
 c
-
se
ct
io
n.
C
ar
di
og
en
ic
 s
ho
ck
N
on
e
L
ev
os
im
en
da
n
T
T
E
: 
B
i-
ve
nt
ri
cu
la
r 
im
pa
ir
m
en
t 
(L
V
E
F
 <
15
%
).
 
C
T
: 
L
un
g 
co
ns
ol
id
at
io
n,
 n
o 
P
E
. 
C
T
C
A
: 
no
 s
te
no
se
s.
 
S
ca
n 
1(
IC
U
 +
 3
da
ys
, 
T
nT
 ?
?n
g/
l)
: 
L
V
E
F
62
%
, 
el
ev
at
ed
 
T
1 
an
d 
T
2,
 e
xt
en
si
ve
 m
id
w
al
l 
an
d 
ep
ic
ar
di
al
 L
G
E
. 
S
ca
n 
2 
(6
w
ee
ks
 a
ft
er
 d
is
ch
ar
ge
):
  
L
V
E
F
 6
3%
, 
no
rm
al
 T
1 
an
d 
T
2,
  
re
so
lu
ti
on
 o
f 
L
G
E
.
C
R
P
 1
90
 m
g/
L
; 
T
nT
 4
06
 n
g/
L
; 
F
er
ri
ti
n 
11
1 
m
cg
/L
; 
ne
ut
ro
ph
il
s 
13
x1
09
/l
R
T
-P
C
R
: 
3 
x 
ne
ga
ti
ve
; 
an
ti
bo
dy
 n
eg
at
iv
e
4 
da
ys
; 
fu
ll
 
re
co
ve
ry
C
as
e 
9:
 3
6;
 m
al
e;
 B
la
ck
-A
fr
ic
an
; 
no
 P
M
H
N
o 
pr
od
ro
m
al
 s
ym
pt
om
s
7-
da
y 
fe
ve
r,
 h
ea
da
ch
e 
an
d 
m
al
ai
se
, 
 2
-d
ay
s 
vo
m
it
in
g,
 u
pp
er
 
ab
do
m
in
al
 p
ai
n 
an
d 
lo
os
e 
st
oo
ls
. 
 
C
ar
di
og
en
ic
 s
ho
ck
N
on
e
N
on
e
T
T
E
: 
B
i-
ve
nt
ri
cu
la
r 
im
pa
ir
m
en
t 
(L
V
E
F
 <
35
%
).
 
C
X
R
 -
 s
ub
tl
e 
bi
ba
sa
l 
ch
an
ge
s
S
ca
n 
1(
IC
U
 +
 4
 d
ay
s)
: 
L
V
E
F
58
%
, 
el
ev
at
ed
 T
2,
 
ex
rt
en
si
ve
 m
id
w
al
l 
L
G
E
. 
C
R
P
 2
22
 m
g/
L
; 
T
nT
 2
70
4 
ng
/L
; 
F
er
ri
ti
n 
38
47
 
m
cg
/L
; 
ne
ut
ro
ph
il
s 
10
x1
09
/l
R
T
-P
C
R
: 
3 
x 
ne
ga
ti
ve
; 
an
ti
bo
dy
 n
eg
at
iv
e
1 
da
y;
 n
o 
fo
ll
ow
 u
p 
da
ta
C
as
e 
10
: 
21
; 
m
al
e;
 B
la
ck
-
A
fr
ic
an
; 
as
th
m
a 
an
d 
fa
m
il
y 
hi
st
or
y 
of
 d
il
at
ed
 
ca
rd
io
m
yo
pa
th
y 
an
d 
pr
em
at
ur
e 
su
dd
en
 d
ea
th
N
o 
pr
od
ro
m
al
 s
ym
pt
om
s
2-
4 
w
ee
ks
 d
ys
pn
oe
a,
 
pe
ri
ph
er
al
 o
ed
em
a,
 c
he
st
 
pa
in
C
ar
di
og
en
ic
 s
ho
ck
N
on
e
M
il
ri
no
ne
; 
B
S
A
; 
m
et
hy
lp
re
dn
is
ol
on
e
T
T
E
: 
B
i-
ve
nt
ri
cu
la
r 
im
pa
ir
m
en
t 
(L
V
E
F
15
%
).
 
C
T
: 
pu
lm
on
ar
y 
oe
de
m
a 
+
/-
co
ns
ol
id
at
io
n 
. 
N
o 
sc
an
 o
bt
ai
ne
d.
 E
xp
la
nt
 h
ea
rt
: 
ex
te
ns
iv
e 
fi
br
ot
ic
 
ch
an
ge
s,
 n
o 
in
fl
am
m
at
or
y 
in
fi
lt
ra
te
s.
 G
en
et
ic
 t
es
t 
pe
nd
in
g.
C
R
P
 1
03
m
g/
L
; 
T
nT
 9
5 
ng
/L
; 
F
er
ri
ti
n 
18
2 
m
cg
/L
; 
ne
ut
ro
ph
il
s 
8x
10
9/
l
R
T
-P
C
R
: 
5 
x 
ne
ga
ti
ve
; 
an
ti
bo
dy
 p
os
it
iv
e
2 
da
ys
; 
 
ca
rd
ia
c 
tr
an
sp
la
nt
 2
0 
da
ys
 a
ft
er
  
ad
m
is
si
io
n
C
as
e 
11
: 
59
; 
m
al
e;
 B
la
ck
-
A
fr
ic
an
; 
D
M
 I
I,
 C
K
D
, 
ob
es
it
y,
 
pe
rf
or
at
ed
 d
uo
de
na
l 
ul
ce
r
R
T
-P
C
R
 p
ro
ve
n 
C
O
V
I1
9 
 2
 
m
on
th
s 
pr
io
r,
 c
om
pl
ic
at
ed
 b
y 
pe
rf
or
at
ed
 u
lc
er
 a
nd
 l
ap
ar
ot
om
y.
3 
da
ys
 d
ys
pn
oe
a,
 p
ed
al
 
an
d 
sc
ro
ta
l 
oe
de
m
a
R
es
pi
ra
to
ry
 f
ai
lu
re
 
N
on
e
B
S
A
, 
os
el
ta
m
iv
ir
T
T
E
: 
B
i-
ve
nt
ri
cu
la
r 
im
pa
ir
m
en
t 
(L
V
E
F
<
15
%
).
 
C
T
: 
m
ul
ti
fo
ca
l 
gr
ou
nd
-g
la
ss
 
ch
an
ge
s.
 
S
ca
n 
1(
IC
U
 +
 1
5 
da
ys
):
 L
V
E
F
16
%
, 
m
il
dl
y 
el
ev
at
ed
 T
1,
 
no
rm
al
  
T
2,
 n
o 
L
G
E
. 
C
R
P
 3
4m
g/
L
; 
T
nT
 9
5 
ng
/L
; 
F
er
ri
ti
n 
10
74
 
m
cg
/L
; 
ne
ut
ro
ph
il
s 
4x
10
9/
l
R
T
-P
C
R
: 
1 
x 
ne
ga
ti
ve
; 
an
ti
bo
dy
 p
os
it
iv
e
2 
da
ys
; 
ch
ro
ni
c 
he
ar
t 
fa
il
ur
e 
sy
m
pt
om
s
C
as
e1
2:
 2
0;
 f
em
al
e;
 B
la
ck
-
A
fr
ic
an
; 
no
 P
M
H
N
o 
pr
od
ro
m
al
 s
ym
pt
om
s
1m
on
th
  
ch
es
t 
pa
in
 a
nd
 
w
or
se
ni
ng
 d
ys
pn
oe
a 
an
d 
or
th
op
no
ea
M
ob
it
z 
2 
A
V
 b
lo
ck
, 
hy
po
te
ns
io
n,
 
m
on
it
or
in
g 
fo
ll
ow
in
g 
ca
rd
ia
c 
bi
op
sy
N
on
e
m
et
hy
lp
re
dn
is
ol
on
e
T
T
E
: 
B
i-
ve
nt
ri
cu
la
r 
im
pa
ir
m
en
t 
(L
V
E
F
<
45
%
).
 
C
X
R
: 
pl
eu
ra
l 
ef
fu
si
on
s 
 
S
ca
n 
1(
IC
U
 -
 1
 d
ay
, 
T
nT
 2
74
1n
g/
l)
: 
L
V
E
F
33
%
, 
ve
ry
 
el
ev
at
ed
 T
1 
an
d 
T
2,
 n
o 
L
G
E
. 
S
ca
n 
2 
(I
C
U
 +
 6
 d
ay
s,
 
T
nT
 3
8n
g/
l)
  
L
V
E
F
 6
6%
, 
m
il
dl
y 
el
ev
at
ed
 T
1 
an
d 
T
2,
 
no
 L
G
E
. 
E
M
B
 (
IC
U
 d
ay
 0
):
 l
ym
ph
oc
yt
ic
 m
yo
ca
rd
it
is
.
C
R
P
 5
m
g/
L
; 
T
nT
 
27
41
 n
g/
L
; 
F
er
ri
ti
n 
92
 m
cg
/L
; 
ne
ut
ro
ph
il
s 
4x
10
9/
l
R
T
-P
C
R
: 
3 
x 
ne
ga
ti
ve
; 
an
ti
bo
dy
 p
os
it
iv
e
1 
da
y;
 n
o 
fo
ll
ow
 u
p 
da
ta
A
g
e;
 G
en
d
er
; 
E
th
n
ic
it
y
; 
P
M
H
.
L
ab
. 
R
es
u
lt
s 
(p
ea
k
 v
al
u
es
)
S
A
R
S
-C
o
V
-2
 
R
es
u
lt
s
IC
U
 s
ta
y
; 
o
u
tc
o
m
e 
C
li
n
ic
al
 P
re
se
n
ta
ti
o
n
IC
U
 S
u
p
p
o
rt
 (
le
n
g
th
)
M
y
o
ca
rd
ia
l 
Im
ag
in
g
